In the histopathologic assessment of breast cancer, the standard markers ER, PR, and HER2 identify drug targets, as ER-positive tumors are candidates for anti-estrogen treatment whereas HER2-positive tumors are candidates for treatment with trastuzumab. The gene discussed is ERBB2; the disease is breast carcinoma.